Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
In patients naive to treatment or after a 2-week washout period for patients whose treatment
was ineffective, the use of olmesartan was assessed in a 4-phase treatment scheme:
monotherapy, addition of hydrochlorothiazide (2 phases), addition of amlodipine.
Phase:
Phase 4
Details
Lead Sponsor:
Daiichi Sankyo Inc. Daiichi Sankyo, Inc.
Treatments:
Amlodipine Angiotensin II Type 1 Receptor Blockers Hydrochlorothiazide Olmesartan Olmesartan Medoxomil